Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Price Target to $14.00
Eye Drop in Phase 2 Clinical Testing for Treatment of Wet-AMD
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 07/31/13 -- announced today that it has updated coverage on (NASDAQ: OHRP) ("The Company" or "OHR") and raised its twelve month price target of from $10.50 to $14.00. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is focused on developing Squalamine Eye Drops, in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD). Therapies for Wet-AMD such as ranibizumab (Lucentis®) sold by (acquired by Roche), as well as aflibercept (Eylea®) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $5B of revenues in 2012. OHR's Wet-AMD clinical candidate Squalamine eye drops would seem to present a significant advantage relative to the aforementioned therapies considering the delivery method which is self-administered eye drops. Both Lucentis® and Eylea® require an injection into the back of the eye. The Squalamine Eye Drop program has the potential to create a monumental shift in the way patients are treated for Wet-AMD." Mr. Silver concludes, "OHR recently completed an up-listing to the Nasdaq, added two prestigious Board members including , the former President of Global Pharmaceuticals for and strengthened its balance sheet, which according to the Company, gives them a cash runway into 2015."
To download a FREE copy of the Ohr Pharmaceutical, Inc. research report, please visit and click the "Download" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of .
Please follow us on Twitter (at)VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more...
Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website .
Contact:
Vista Partners LLC
877.215.4813
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 31.07.2013 - 07:15 Uhr
Sprache: Deutsch
News-ID 1250423
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 214 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Price Target to $14.00
"
steht unter der journalistisch-redaktionellen Verantwortung von
Vista Partners LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
